Clinical trial · Observational
Clinical Intervention Strategy for High-risk Group of Hepatitis B Related Hepatocellular Carcinoma
Clinical Intervention Strategy for High-risk Hepatitis B Related Hepatocellular Carcinoma Based on Liquid Biopsy Screening Technique
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to explore whether there is difference in the incidence rate and incidence rate of HCC in patients with chronic hepatitis B who are screened for high risk of liver cancer. Whether the timely intervention can be used to reduce the incidence of HCC for the early screening and early warning patients can provide evidence-based medical evidence for the selection or adjustment of anti HBV drugs in high-risk patients with liver cancer. To provide evidence for whether patients with liver nodules at high risk of liver cancer need to deal with liver nodules in advance.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Time | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Long term follow-up | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Observation group
- description
- Those who did not deal with nodules and were closely followed up.
- label
- Treatment group
- description
- Patients with liver nodules were treated by radiofrequency ablation or/and surgery and so on.
- interventionNames
- Other: Long term follow-up
Primary outcomes (2)
- measure
- The patients' enrollment time.
- timeFrame
- up to 3 years.
- description
- The time of all patients when they were enrolled.
- measure
- Time the patients were diagnosed.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Willing and able to sign informed consent * Male or female, 18 ≤ age≤ 75 * The diagnosis was in accordance with the 2019 guidelines for the diagnosis and treatment of chronic hepatitis B and received anti HBV treatment for 48 weeks; * Imaging examination showed liver nodules or space occupying lesions (any imaging examination of abdominal color Doppler ultrasound, CT and MRI), and imaging examination could not determine the benign and malignant of the lesions * The estimated survival time is more than half a year * Peripheral blood cfdna gene screening is high risk * Full capacity for civil conduct Exclusion Criteria: * Primary liver cancer was diagnosed or supported by the following evidence: elevated alpha fetoprotein (AFP \> 100ng / ml) or liver imaging showed clear liver cancer nodules in the liver * Have a history of malignant tumors within 5 years before screening, except for specific cancers cured by surgical resection (such as basal cell skin cancer, etc.) * Current or previous history of major diseases that may interfere with personal treatment, evaluation or compliance. Major diseases are 25 major diseases specified by the CIRC * Combined with HCV, HIV, HDV or other infectious diseases * Severe lung disease, severe heart disease or genetic metabolic disease * Psychiatric hospitalization, attempted suicide and / or temporary disability due to mental illness in the past 5 years * Combined with autoimmune liver disease, alcoholic liver disease and drug-induced liver injury * Pregnant or lactating women * The researcher believes that it is not suitable to participate in this experiment.
References
Publications (0)
Data not yet available